Around 70% of ABclonal’s clients have therapeutic goals for their monoclonal antibody development projects. The effects of the therapeutic lead candidates can be evaluated using antibodies recognizing unique variable regions in each candidate, known as anti-idiotype (anti-ID) antibodies. Anti-ID antibodies can be used to identify, neutralize, block, and assess drug-to-analyte binding properties on the target therapeutic antibody.
Useful in anti-drug antibody (ADA) and pharmacokinetic (PK) analysis, anti-idiotype antibodies help provide information about how the drug is absorbed, distributed, metabolized, and eliminated in the patient’s body. These assays and studies help optimize the antibody-based drugs to ensure patients receive safe and effective treatments.
With over 90% success in generating the desired responses in anti-ID antibodies, ABclonal prepares you to successfully detect, identify, and analyze therapeutic drugs to support your upcoming preclinical and downstream clinical trials.